The world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has continued to assert its dominance in the weight-loss and diabetes drug market in 2026.
The company’s most recent earnings report forecast robust 25% growth for the year, well above expectations. While this would be much slower than the 45% growth Lilly generated in 2025, it would still mark the company’s third-highest annual growth rate in its history. The firm’s current GLP-1 franchises will continue to see strong sales increases, but growth can’t remain in sky-high territory forever.
